Mendus
0,449 SEK -5,38%24 investorer følger denne virksomhed
Mendus develops cancer immunotherapies with a focus on the prevention of tumor recurrence, the leading cause of cancer-related deaths globally. Indications include acute myeloid leukemia, ovarian cancer and soft tissue sarcomas. The company previously went by the name Immunicum and was renamed Mendus following the merger with the Dutch private company DCprime in 2021. Mendus today has its headquarters in Stockholm and its operational activities in Leiden, The Netherlands.
P/E (24e)
-3,58
EV/EBIT (adj.) (24e)
-3,05
P/B (24e)
0,69
Udbytteafkast, % (24e)
-
Kursmål
0.70 SEK
Anbefaling
Akkumulér
Opdateret
10.4.2024
NASDAQ Stockholm
IMMU
Daglig lav / høj pris
0,446 / 0,477
SEK
Markedsværdi
451,73 mio. SEK
Aktieomsætning
365,78 t SEK
Volumen
797 t
Business risk
Valuation risk
Current
Previous
Seneste analyser
Extensive report
Inderes' extensive report is an investor's handbook on customer companies covered by our research.
The latest extensive report was released
Read the reportAnalyst
Antti Siltanen
Analytiker
Seneste videoer
Finanskalender
Generalforsamling
17.05.2024
Delårsrapport
17.05.2024
Delårsrapport
23.08.2024
Delårsrapport
08.11.2024
Årsrapport
13.02.2025
Større aktionærerKilde: Millistream Market Data AB
Ejer | Kapital | Stemmer |
---|---|---|
Adrianus Van Herk | 34,6 % | 34,6 % |
Thomas Eldered | 21,7 % | 21,7 % |
Premium
This content is for our Premium customers only.
Resultatopgørelse
2020 | 2021 | 2022 | 2023 | 2024e | 2025e | 2026e | 2027e | |
---|---|---|---|---|---|---|---|---|
Omsætning | 0,0 | 0,0 | 0,0 | 0,0 | 0,0 | 0,0 | 0,0 | 0,0 |
vækst-% | 150,0 % | -60,0 % | 150,0 % | |||||
EBITDA | -86,9 | -132,0 | -138,5 | -133,2 | -123,8 | -123,0 | -93,0 | -95,3 |
EBIT (adj.) | -86,0 | -130,1 | -133,7 | -125,9 | -123,8 | -123,0 | -93,0 | -95,3 |
EBIT | -86,0 | -130,1 | -133,7 | -125,9 | -123,8 | -123,0 | -93,0 | -95,3 |
Overskud før skat | -89,2 | -133,4 | -138,8 | -126,9 | -126,2 | -126,0 | -96,0 | -98,3 |
Netto indkomst | -89,2 | -133,4 | -138,8 | -126,9 | -126,2 | -126,0 | -96,0 | -98,3 |
EPS (adj.) | -0,54 | -0,67 | -0,70 | -0,15 | -0,13 | -0,13 | -0,10 | -0,10 |
vækst-% | ||||||||
Udbytte | 0,00 | 0,00 | 0,00 | 0,00 | 0,00 | 0,00 | 0,00 | 0,00 |
Udbytte ratio |
Profitability and return on capital
2020 | 2021 | 2022 | 2023 | 2024e | 2025e | 2026e | 2027e | |
---|---|---|---|---|---|---|---|---|
EBITDA-% | -869.130,0 % | -3.298.775,0 % | -1.385.420,0 % | -1.332.210,0 % | -1.237.780,0 % | -1.229.750,0 % | -930.096,0 % | -953.001,0 % |
EBIT-% (adj.) | -860.270,0 % | -3.252.500,0 % | -1.336.940,0 % | -1.259.210,0 % | -1.237.780,0 % | -1.229.750,0 % | -930.096,0 % | -953.001,0 % |
EBIT-% | -860.270,0 % | -3.252.500,0 % | -1.336.940,0 % | -1.259.210,0 % | -1.237.780,0 % | -1.229.750,0 % | -930.096,0 % | -953.001,0 % |
ROE | -27,2 % | -20,2 % | -23,7 % | -20,8 % | -18,6 % | -21,3 % | -20,0 % | -25,6 % |
ROI | -25,3 % | -19,4 % | -22,3 % | -20,2 % | -18,1 % | -19,7 % | -15,8 % | -16,2 % |
Værdiansættelse
2020 | 2021 | 2022 | 2023 | 2024e | 2025e | 2026e | 2027e | |
---|---|---|---|---|---|---|---|---|
Aktiekurs (SEK) | 6,82 | 3,95 | 2,22 | 0,52 | 0,45 | 0,45 | 0,45 | 0,45 |
Aktier | 166,2 | 199,4 | 199,4 | 836,1 | 1.007,2 | 1.007,2 | 1.007,2 | 1.007,2 |
Markedsværdi | 1.132,6 | 787,0 | 442,7 | 437,3 | 451,7 | 451,7 | 451,7 | 451,7 |
Enterprise value | 988,2 | 631,7 | 430,0 | 316,5 | 377,0 | 502,9 | 599,0 | 697,3 |
EV/S | 98.819,4 | 157.933,9 | 43.002,0 | 31.653,6 | 37.697,3 | 50.294,8 | 59.895,8 | 69.725,8 |
EV/EBITDA | - | - | - | - | - | - | - | - |
EV/EBIT (adj.) | - | - | - | - | - | - | - | - |
EV/EBIT | - | - | - | - | - | - | - | - |
P/E (adj.) | - | - | - | - | - | - | - | - |
P/E | - | - | - | - | - | - | - | - |
P/B | 1,7 | 1,2 | 0,9 | 0,6 | 0,7 | 0,9 | 1,0 | 1,4 |
P/S | 113.259,4 | 196.758,9 | 44.267,0 | 43.730,5 | 45.172,5 | 45.172,5 | 45.172,5 | 45.172,5 |
Udbytteprocent | ||||||||
Equity ratio | 90,7 % | 91,1 % | 82,9 % | 93,2 % | 91,9 % | 82,3 % | 67,4 % | 52,1 % |
Gearing ratio | -21,8 % | -23,6 % | -2,5 % | -17,1 % | -11,4 % | 9,7 % | 34,0 % | 73,5 % |
Kvartalsdata
Q1/23 | Q2/23 | Q3/23 | Q4/23 | 2023 | Q1/24e | Q2/24e | Q3/24e | Q4/24e | |
---|---|---|---|---|---|---|---|---|---|
Omsætning | 0,0 | 0,0 | 0,0 | ||||||
EBITDA | -31,2 | -30,2 | -29,0 | -42,7 | -133,2 | -28,6 | -31,0 | -32,0 | -32,3 |
EBIT | -29,6 | -27,7 | -25,9 | -42,7 | -125,9 | -28,6 | -31,0 | -32,0 | -32,3 |
Overskud før skat | -30,2 | -3,3 | -52,2 | -41,2 | -126,9 | -29,2 | -31,6 | -32,6 | -32,9 |
Netto indkomst | -30,2 | -3,3 | -52,2 | -41,2 | -126,9 | -29,2 | -31,6 | -32,6 | -32,9 |
ViserAlle indholdstyper
Mendus publishes Annual Report for 2023
Mendus: Changing the course of cancer treatment
Join Inderes community
Don't miss out - create an account and get all the possible benefits
Inderes account
Followings and notifications on followed companies
Analyst comments and recommendations
Stock comparison tool & other popular tools